Dr. So-Yeon Kang

speaker

80 appearances 1 recordings 1 series first heard Jul 2026 last heard 13 Jul

Dr. So-Yeon Kang’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 1 in all, peaking in Jul 2026 with 1.

Appearances

newest first · ▶ plays the moment

Science Friday · China's booming biotech, from a brain implant to drug discovery · 13 Jul 2026 podcast

But that's not something that any people or the stakeholders in this ecosystem want to see because

As I mentioned earlier, this is about innovation and science and completely banning or disrupting this sort of, you know, the natural economy and also the economic behaviors that can have sort of unintended consequences on patients' access to needed treatments, right?

So that approach should be very, very careful.

And we want to approach this as sort of, you know, competition as perspective, not as sort of, you know,

Some trade war or any sort of, you know, banning the transactions.

In theory, if we obtain the trucks developed in lower cost setting, then we may want to see that the truck actual price lower than in the previous settings, right?

But now we don't have any evidence to support any direction.

And also, from the manufacturer's perspective, there may not be the motivation for them to lower the price, right?

Because as I mentioned, Bristol-Myers Squibb paid $15 billion, right?

So it's no lower than any other deals that they did made with other American companies too.

So for them, a lower industrial price is not, I don't think that it's on their agenda.

Absolutely.

So there's lots of, you know, discussion about how to coordinate and harmonize this regulatory systems and also how to co-develop drugs.

So there are ongoing some parallel discussion about this.

But in the meantime, we need to pay attention to how we can make this in the U.S.

system stronger, because, you know, this innovation does.

is a sort of long game.

And once we lose the sort of resource and infrastructure, it's really hard to rebuild.

So what are the kind of consequences and implications of this shift on the U.S.

ecosystem, as well as the local economy supporting this biopharmaceutical innovation?

Showing 61–80 of 80 · page 4 of 4